Kesimpta shows promise in controlling MS in swiss study
NCT ID NCT05285904
First seen Jan 06, 2026 · Last updated May 20, 2026 · Updated 18 times
Summary
This study observed 107 Swiss adults with relapsing multiple sclerosis who were already taking Kesimpta (ofatumumab) for at least 3 months. Researchers tracked how well the drug controlled their disease, looking for signs like relapses, new brain lesions, or worsening disability. The goal was to see how effective Kesimpta is in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Baden, Canton of Aargau, 5405, Switzerland
-
Novartis Investigative Site
Lucerne, Canton of Lucerne, 6004, Switzerland
-
Novartis Investigative Site
Lucerne, Canton of Lucerne, 6006, Switzerland
-
Novartis Investigative Site
Sargans, Canton of St. Gallen, 7320, Switzerland
-
Novartis Investigative Site
Gland, Canton of Vaud, 1196, Switzerland
-
Novartis Investigative Site
Zurich, Canton of Zurich, 8006, Switzerland
-
Novartis Investigative Site
Zurich, CHE, 8001, Switzerland
-
Novartis Investigative Site
Basel, 4001, Switzerland
-
Novartis Investigative Site
Bern, 3010, Switzerland
-
Novartis Investigative Site
Lausanne, 1011, Switzerland
-
Novartis Investigative Site
Lucerne, 6000, Switzerland
-
Novartis Investigative Site
Lugano, 6900, Switzerland
-
Novartis Investigative Site
Zurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.